AA
PFE icon

Acorns Advisers’s Pfizer PFE Stock Holding History

Acorns Advisers’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$457K Buy
18,973
+2,429
+15% +$63.5K ﹤0.01% 78
2026
Q1 		$465K Buy
16,544
+946
+6% +$25.2K ﹤0.01% 69
2025
Q4 		$388K Buy
15,598
+1,106
+8% +$27.9K ﹤0.01% 72
2025
Q3 		$369K Buy
14,492
+1,989
+16% +$49.1K ﹤0.01% 67
2025
Q2 		$303K Buy
12,503
+3,087
+33% +$72K ﹤0.01% 68
2025
Q1 		$239K Buy
9,416
+893
+10% +$23.4K ﹤0.01% 68
2024
Q4 		$226K Buy
+8,523
New +$231K ﹤0.01% 63

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Acorns Advisers's PFE Position: Q2 2026 in Review

Acorns Advisers increased its Pfizer (PFE) stake by 15% in Q2 2026, buying an estimated $63.5K and bringing the position to 18,973 shares worth $457K. The position accounts for ﹤0.01% of the portfolio, ranked #78.

Acorns Advisers first reported a position in PFE in Q4 2024 and has held it in 7 quarters since. The position peaked at $465K in Q1 2026. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Acorns Advisers held 18,973 shares of Pfizer worth $457K as of Q2 2026.
  • Acorns Advisers bought 2,429 Pfizer shares in Q2 2026, an estimated $63.5K.
  • Pfizer made up ﹤0.01% of Acorns Advisers's portfolio in Q2 2026, its #78 holding.
  • Acorns Advisers first reported a position in Pfizer in Q4 2024 and has held it in 7 quarters since.
  • Acorns Advisers's Pfizer position peaked at $465K in Q1 2026.
  • 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Acorns Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.